Analysis of metabolic response (MR) by positron emission tomography (PET) compared with tumor response by computed tomography (CT) from MPACT, a phase III trial comparing nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone for patients (pts) with metastatic adenocarcinoma of the pancreas

被引：0
|
作者：
Ramanathan, Ramesh K.
Von Hoff, Daniel D.
Moore, Malcolm J.
Teixeira, Luis
Siena, Salvatore
Tabernero, Josep
Goldstein, David
Wei, Xinyu
Lu, Brian
机构：
[1] Virginia G Piper Canc Ctr, Translat Genom Res Inst, Scottsdale, AZ USA
[2] Scottsdale Healthcare TGen, Virginia G Piper Canc Ctr Clin Trials, Scottsdale, AZ USA
[3] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[4] Hop St Antoine, F-75571 Paris, France
[5] Osped Niguarda Ca Granda, Falck Div Med Oncol, Milan, Italy
[6] Vall dHebron Univ Hosp, Barcelona, Spain
[7] Prince Wales Hosp, Sydney, NSW, Australia
[8] Celgene Corp, Summit, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 03期
关键词：
D O I：
10.1200/jco.2014.32.3_suppl.254
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
254
引用
收藏
页数：1
相关论文
共 42 条
  • [31] nab-Paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC): Interim efficacy and safety results from the Phase 2 LAPACT Trial
    Philip, P. A.
    Lacy, J.
    Portales, F.
    Sobrero, A.
    Pazo-Cid, R.
    Manzano Mozo, J. L.
    Kim, E. S.
    Dowden, S.
    Zakari, A.
    Borg, C.
    Terrebonne, E.
    Rivera Herrero, F.
    Shiansong Li, J.
    Ong, T. J.
    Nydam, T.
    Hammel, P.
    ANNALS OF ONCOLOGY, 2017, 28
  • [32] Phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P plus Gem) versus gemcitabine (Gem) alone for patients with resected pancreatic cancer (PC): Outcomes by geographic region.
    Reni, Michele
    Riess, Hanno
    O'Reilly, Eileen Mary
    Park, Joon Oh
    Hatoum, Hassan
    Saez, Berta Laquente
    Salminen, Tapio
    Oettle, Helmut
    Lopez, Rafael
    Dowden, Scot D.
    Karthaus, Meinolf
    Tabernero, Josep
    Van Cutsem, Eric
    Philip, Philip Agop
    Goldstein, David
    Berlin, Jordan
    Tempero, Margaret A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [33] Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT)
    Goldstein, David
    Von Hoff, Daniel D.
    Moore, Malcolm
    Greeno, Edward
    Tortora, Giampaolo
    Ramanathan, Ramesh K.
    Macarulla, Teresa
    Liu, Helen
    Pilot, Richard
    Ferrara, Stefano
    Lu, Brian
    EUROPEAN JOURNAL OF CANCER, 2016, 52 : 85 - 91
  • [34] nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial (vol 33, pg 747, 2016)
    Tehfe, Mustapha
    Dowden, Scot
    Kennecke, Hagen
    El-Maraghi, Robert
    Lesperance, Bernard
    Couture, Felix
    Letourneau, Richard
    Liu, Helen
    Romano, Alfredo
    ADVANCES IN THERAPY, 2017, 34 (01) : 277 - 279
  • [35] NAB-PACLITAXEL PLUS GEMCITABINE VS GEMCITABINE ALONE FOR PATIENTS WITH METASTATIC PANCREATIC CANCER: INFLUENCE OF PRIMARY PANCREATIC TUMOR LOCATION ON EFFICACY AND TREATMENT EXPOSURE IN THE MPACT PHASE III TRIAL
    Jose, Lopez-Martin
    Wee, Ma Wen
    Christos, Karapetis
    Peter, Balcke
    Hagan, Kennecke
    Michael, Stahl
    Michele, Milella
    Francis, Nugent
    Diane, Prager
    Brian, Lu
    Stefano, Ferrara
    Darryl, Penenberg
    Daniel, Von Hoff
    ANNALS OF ONCOLOGY, 2014, 25 : 28 - 28
  • [36] Interim health related quality of life (QoL) from LAPACT, a Phase 2 trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC)
    Portales, F.
    Philip, P. A.
    Hammel, P.
    Buscaglia, M.
    Pazo-Cid, R.
    Manzano Mozo, J. L.
    Kim, E. S.
    Dowden, S.
    Zakari, A.
    Borg, C.
    Terrebonne, E.
    Rivera Herrero, F.
    Li, J. Shiansong
    Ong, T. J.
    Nydam, T.
    Lacy, J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [37] Real-world analysis of treatment patterns examining nab-Paclitaxel plus gemcitabine (nab-P plus G) versus gemcitabine monotherapy (G) in first-line treatment of metastatic pancreatic adenocarcinoma (MPAC) in a US community oncology setting
    Braiteh, Fadi S.
    Patel, Manish
    Parisi, Monika
    Ni, Quanhong
    Park, Si Yeon
    Faria, Claudio
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [38] Napabucasin plus nab-paclitaxel with gemcitabine in patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC): Results from the phase III CanStem111P study
    Bekaii-Saab, T.
    Okusaka, T.
    Goldstein, D.
    Oh, D-Y.
    Ueno, M.
    Ioka, T.
    Fang, W.
    Anderson, E. C.
    Noel, M. S.
    Reni, M.
    Choi, H. J.
    Goldberg, J.
    Oh, S. C.
    Li, C-P.
    Tabernero, J.
    Li, J.
    Foos, E.
    Oh, C.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2021, 32 : S1084 - S1085
  • [39] CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer
    Chiorean, E. G.
    Von Hoff, D. D.
    Reni, M.
    Arena, F. P.
    Infante, J. R.
    Bathini, V. G.
    Wood, T. E.
    Mainwaring, P. N.
    Muldoon, R. T.
    Clingan, P. R.
    Kunzmann, V.
    Ramanathan, R. K.
    Tabernero, J.
    Goldstein, D.
    McGovern, D.
    Lu, B.
    Ko, A.
    ANNALS OF ONCOLOGY, 2016, 27 (04) : 654 - 660
  • [40] Efficacy, Safety and Pharmacokinetics (PK) of Weekly nab-paclitaxel (P) Plus Gemcitabine (G) in Japanese Patients (pts) With Metastatic Pancreatic Cancer (MPC): Phase I/II Trial
    Kasuga, A.
    Ueno, H.
    Ikeda, M.
    Ueno, M.
    Mizuno, N.
    Ioka, T.
    Omuro, Y.
    Nakajima, T. E.
    Furuse, J.
    PANCREAS, 2014, 43 (08) : 1374 - 1374
12345